164 related articles for article (PubMed ID: 36033258)
1. Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients.
Dawood RM; El-Meguid MA; Shousha HI; Elsayed A; Nabeel MM; Yosry A; Abdelaziz A; Salum GM
Heliyon; 2022 Aug; 8(8):e10119. PubMed ID: 36033258
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals.
Syed T; Fazili J; Ali IA; Zhao D; Hughes D; Mahmood S
Cureus; 2018 Jun; 10(6):e2843. PubMed ID: 30280052
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
5. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
6. Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study.
Ciancio A; Ribaldone DG; Spertino M; Risso A; Ferrarotti D; Caviglia GP; Carucci P; Gaia S; Rolle E; Sacco M; Saracco GM
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672675
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.
Lim N; Singh D; Jackson S; Lake JR
Gastrointest Tumors; 2020 Oct; 7(4):134-143. PubMed ID: 33173777
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study.
Tao XM; Zeng MH; Zhao YF; Han JX; Mi YQ; Xu L
World J Hepatol; 2024 Jan; 16(1):41-53. PubMed ID: 38313240
[TBL] [Abstract][Full Text] [Related]
9. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
10. Development of a gene signature for predicting cirrhosis risk score of chronic liver disease associated with HCV infection in Egyptians.
Dawood RM; Salum GM; El-Meguid MA; Elsayed A; Yosry A; Abdelaziz A; Shousha HI; Nabeel MM; El Awady MK
Microb Pathog; 2021 Apr; 153():104805. PubMed ID: 33609649
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
Sapena V; Enea M; Torres F; Celsa C; Rios J; Rizzo GEM; Nahon P; Mariño Z; Tateishi R; Minami T; Sangiovanni A; Forns X; Toyoda H; Brillanti S; Conti F; Degasperi E; Yu ML; Tsai PC; Jean K; El Kassas M; Shousha HI; Omar A; Zavaglia C; Nagata H; Nakagawa M; Asahina Y; Singal AG; Murphy C; Kohla M; Masetti C; Dufour JF; Merchante N; Cavalletto L; Chemello LL; Pol S; Crespo J; Calleja JL; Villani R; Serviddio G; Zanetto A; Shalaby S; Russo FP; Bielen R; Trevisani F; Cammà C; Bruix J; Cabibbo G; Reig M
Gut; 2022 Mar; 71(3):593-604. PubMed ID: 33741640
[TBL] [Abstract][Full Text] [Related]
12. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
[TBL] [Abstract][Full Text] [Related]
16. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma.
Tajiri K; Ito H; Kawai K; Kashii Y; Hayashi Y; Murayama A; Minemura M; Takahara T; Shimizu Y; Yasuda I
World J Hepatol; 2022 Jun; 14(6):1190-1199. PubMed ID: 35978673
[TBL] [Abstract][Full Text] [Related]
17. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
18. Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals.
Macek Jílková Z; Seigneurin A; Coppard C; Ouaguia L; Aspord C; Marche PN; Leroy V; Decaens T
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33352852
[TBL] [Abstract][Full Text] [Related]
19. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis.
El Kassas M; Funk AL; Salaheldin M; Shimakawa Y; Eltabbakh M; Jean K; El Tahan A; Sweedy AT; Afify S; Youssef NF; Esmat G; Fontanet A
J Viral Hepat; 2018 Jun; 25(6):623-630. PubMed ID: 29274197
[TBL] [Abstract][Full Text] [Related]
20. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.
Salama II; Raslan HM; Abdel-Latif GA; Salama SI; Sami SM; Shaaban FA; Abdelmohsen AM; Fouad WA
World J Hepatol; 2022 Jun; 14(6):1053-1073. PubMed ID: 35978668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
